Gene · 10683
Papers2,335
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,335
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events. | Front Pharmacol | 2026 | 42358360 | PubTator, text mining | PubMed |
| Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma. | Oncology (Williston Park) | 2026 | 42329247 | PubTator, text mining | PubMed |
| Esophageal Small Cell Carcinoma: From Bench Discoveries to Bedside Therapeutics. | Int J Biol Sci | 2026 | 42328440 | PubTator, text mining | PubMed |
| A decade of progress in small-cell lung cancer (2015-2025): a narrative review. | Eur J Clin Pharmacol | 2026 | 42324360 | PubTator, text mining | PubMed |
| Tarlatamab in Previously Treated Small Cell Lung Cancer: A Real-World Experience in a Predominantly Hispanic Population with CNS Metastases. | Cancers (Basel) | 2026 | 42279394 | PubTator, text mining | PubMed |
| DLL3 Expression in a Genotyped Cohort of Sporadic Medullary Thyroid Carcinomas. | Am J Surg Pathol | 2026 | 42252962 | PubTator, text mining | PubMed |
| Updates in Small Cell Lung Cancer Treatment: No Longer Too Small to Ignore-A Review of Recent Therapeutic Advances. | Am Soc Clin Oncol Educ Book | 2026 | 42228883 | PubTator, text mining | PubMed |
| Overcoming immunotherapy resistance in extensive-stage small cell lung cancer: Insights into mechanisms and therapeutic opportunities. | Crit Rev Oncol Hematol | 2026 | 42225194 | PubTator, text mining | PubMed |
| Advances in Pharmacological Treatment of Thoracic Malignancies. | Juntendo Med J | 2026 | 42211160 | PubTator, text mining | PubMed |
| The Role of PET Tracers in Small-Cell Prostate Cancer (SCPC): An Overview in Clinical and Preclinical Settings. | Cancers (Basel) | 2026 | 42193004 | PubTator, text mining | PubMed |
| Immunotherapeutic strategies in gastroenteropancreatic neuroendocrine neoplasms: present condition and future developments. | J Chemother | 2026 | 42186251 | PubTator, text mining | PubMed |
| Assessment of delta-like ligand 3 (DLL3) immunostaining in neuroendocrine tumors of the gynecological tract and comparing expression with other high-grade gynecological malignancies. | Ann Diagn Pathol | 2026 | 42172687 | PubTator, text mining | PubMed |
| Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies. | Front Oncol | 2026 | 42147254 | PubTator, text mining | PubMed |
| Small cell lung cancer: a therapeutic update in the era of immunotherapy and beyond-a narrative review. | Chin Clin Oncol | 2026 | 42145018 | PubTator, text mining | PubMed |
| Management of Medullary Thyroid Carcinoma: Integrating World Health Organization Grading and Molecular Targets for Precision Therapy. | Clin Oncol (R Coll Radiol) | 2026 | 42134278 | PubTator, text mining | PubMed |
| A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib. | Thyroid | 2026 | 42117355 | PubTator, text mining | PubMed |
| Structure-based design and optimization of cyclic peptide ligands targeting delta-like ligand 3. | RSC Adv | 2026 | 42111524 | PubTator, text mining | PubMed |
| Cost-effectiveness of tarlatamab versus chemotherapy for patients with small-cell lung cancer after platinum-based chemotherapy in the United States and China. | Front Pharmacol | 2026 | 42110543 | PubTator, text mining | PubMed |
| Addressing Unmet Needs in the Management of Small Cell Lung Cancer: Treatment of Brain Metastases, Quality of Life, and the Role of Real-World Evidence. | Curr Treat Options Oncol | 2026 | 42105144 | PubTator, text mining | PubMed |
| Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract. | Gynecol Oncol | 2026 | 42102523 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10683/papers?page=4